477 related articles for article (PubMed ID: 20417871)
21. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
22. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
23. Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
Miglino M; Varaldo R; Colombo N; Grasso R; Clavio M; Garuti A; Aquino S; Albarello A; Sessarego M; Gobbi M
J Exp Clin Cancer Res; 2006 Sep; 25(3):321-4. PubMed ID: 17167971
[TBL] [Abstract][Full Text] [Related]
24. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
Kreuzer KA; Le Coutre P; Landt O; Na IK; Schwarz M; Schultheis K; Hochhaus A; Dörken B
Ann Hematol; 2003 May; 82(5):284-9. PubMed ID: 12692682
[TBL] [Abstract][Full Text] [Related]
25. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
26. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
27. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
[TBL] [Abstract][Full Text] [Related]
28. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Kantarjian H; O'Brien S; Shan J; Huang X; Garcia-Manero G; Faderl S; Ravandi-Kashani F; Verstovsek S; Beth Rios M; Cortes J
Cancer; 2008 Feb; 112(4):837-45. PubMed ID: 18085610
[TBL] [Abstract][Full Text] [Related]
30. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Ross DM; Branford S; Moore S; Hughes TP
Leukemia; 2006 Apr; 20(4):664-70. PubMed ID: 16482210
[TBL] [Abstract][Full Text] [Related]
31. RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
Schnittger S; Bacher U; Kern W; Tschulik C; Weiss T; Haferlach C; Haferlach T
Br J Haematol; 2009 Sep; 146(6):665-8. PubMed ID: 19624538
[TBL] [Abstract][Full Text] [Related]
32. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
Ohm L; Arvidsson I; Barbany G; Hast R; Stenke L
Am J Hematol; 2012 Aug; 87(8):760-5. PubMed ID: 22641468
[TBL] [Abstract][Full Text] [Related]
33. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
34. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
35. High-resolution analysis of acquired genomic imbalances in bone marrow samples from chronic myeloid leukemia patients by use of multiple short DNA probes.
Reid AG; Tarpey PS; Nacheva EP
Genes Chromosomes Cancer; 2003 Jul; 37(3):282-90. PubMed ID: 12759926
[TBL] [Abstract][Full Text] [Related]
36. Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases.
Martínez-López J; Ayala R; Albizua Q
Haematologica; 2002 Aug; 87(8):ELT35. PubMed ID: 12161380
[No Abstract] [Full Text] [Related]
37. Unique secondary chromosomal abnormalities are frequently found in the chronic phase of chronic myeloid leukemia in southern Vietnam.
Phan TX; Hoang AV; Huynh VM; Nguyen KT; Nguyen TB; Huynh N; Pham QT; Tran VB; Tran VB; Tokunaga K; Sato Y
Cancer Genet Cytogenet; 2006 Jul; 168(1):59-68. PubMed ID: 16772122
[TBL] [Abstract][Full Text] [Related]
38. Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
Schnittger S; Bacher U; Dicker F; Kern W; Alpermann T; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2010 Oct; 49(10):910-8. PubMed ID: 20607847
[TBL] [Abstract][Full Text] [Related]
39. Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Håkansson P; Nilsson B; Andersson A; Lassen C; Gullberg U; Fioretos T
Genes Chromosomes Cancer; 2008 Apr; 47(4):267-75. PubMed ID: 18181176
[TBL] [Abstract][Full Text] [Related]
40. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Lin Y; Bruyère H; Horsman DE; Pantzar T; Barnett MJ; Hogge DE; Nevill TJ; Nantel SH; Sutherland HJ; Toze CL; Shepherd JD; Lavoie JC; Song KW; Smith CA; Forrest DL
Cancer Genet Cytogenet; 2006 Oct; 170(1):16-23. PubMed ID: 16965950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
